Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arctic Bioscience AS ( (DE:9TD) ) has provided an update.
Arctic Bioscience has been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on 30 January 2026, where its Chief Medical Officer will showcase ABS403, a development project targeting inflammation reduction and neuroprotection in glaucoma, a progressive eye disease with no cure that can lead to blindness. The program, which builds on encouraging clinical signals from a pilot glaucoma study, marks a strategic move to expand the company’s pipeline into ophthalmology, and Arctic Bioscience is actively seeking partners and investors to advance ABS403 into the next phase of clinical development, potentially strengthening its position in innovative eye-care therapeutics.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements based on bioactive marine raw materials. Its pipeline includes HRO350, an oral drug candidate for mild-to-moderate psoriasis, and it markets marine omega-based dietary supplements globally as bulk ingredients and finished products under the ROMEGA brand.
Average Trading Volume: 27,590
Current Market Cap: NOK94.35M
Find detailed analytics on 9TD stock on TipRanks’ Stock Analysis page.